Photo from Thomas Hofmarcher/LinkedIn
Sep 26, 2024, 13:55
Thomas Hofmarcher: My recent working paper on oncology medicines
Thomas Hofmarcher shared a post on LinkedIn:
”Let’s take a closer look at my recent working paper with the OECD – OCDE on oncology medicines. In the next days, I will feature key graphs that support some of our most important findings.
Finding (1/5): As the number of oncology medicines grows and prices rise, the budget impact of new cancer treatments is increasingly influencing reimbursement decisions in OECD countries, making it harder for some to provide fast access to these critical medicines.
Source: Thomas Hofmarcher/LinkedIn
Thomas Hofmarcher is the Research Director at IHE – The Swedish Institute for Health Economics. He focuses on enhancing patient outcomes while taking fiscal realities into account.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 16:02
Nov 13, 2024, 15:56
Nov 13, 2024, 15:46
Nov 13, 2024, 15:32
Nov 13, 2024, 15:29
Nov 13, 2024, 15:25
Nov 13, 2024, 14:55